DAFTAR PUSTAKA

Abdulla, A., Bahmany, S., Wijma, R.A., van der Nagel, B.C.H. and Koch, B.C.P., 2017, Simultaneous determination of nine β-lactam antibiotics in human plasma by an ultrafast hydrophilic-interaction chromatography–tandem mass spectrometry, *Journal of Chromatography B.*, **1060** :138–143

Adam, E.H.K., Elaziz, M.M.A. and Saeed, A.E.M., 2012, Stability study of ciprofloxacin hydrochloride under stress conditions using reverse phase-high performance liquid chromatography method, *Der Pharmacia Sinica*, **3**(2), 217-223

Afonina, I., Tien, B., Nair, Z., Matysik, A., Lam, L.N., Veleba, M., et.al., 2021, The composition and function of Enterococcus faecalis membrane vesicles, *microLife*, **2**, uqab002

Anderson, V.R. and Perry, C.M., 2008, Levofloxacin: A Review of its Use as a High-Dose, Short-Course Treatment for Bacterial Infection, *Drugs*, **68**, 535–565

Ariano, R.E., Nyhlén, A., Donnelly, J.P., Sitar, D.S., Harding, G.K., Zelenitsky, S.A., 2005, Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia, *Annals of Pharmacotherapy*, **39**(1), 32–38

Begg, E.J., Robson, R.A., Saunders, D.A., Graham, G.G., Buttimore, R.C., Neill, A.M. and Ian Town, G., 2000, The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing, *British Journal of Clinical Pharmacology*, **49**, 32–38

Bennett, A.C., Bennett, C.L.,Witherspoon, B.J. and Knopf, K.B., 2019, An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency, *Expert Opinion of Drug Safety*, **18**, 1055–1063

Birken, S.L.K. and Dipiro, J.T., 2005, Septic and Septic Shock, in: *Pharmacotherapy: A Pathophysiologic Approach*., McGraw Hill Professional, Chapter 117, pp. 2175–2187

Blot, S.I., Pea, F. and Lipman, J., 2014, The effect of pathophysiology on pharmacokinetics in the critically ill patient-Concepts appraised by the example of antimicrobial agents, *Advanced drug delivery reviews*, **77**, 3–11

Bradley, J.S., Dudley, M.N. and Drusano, G.L., 2003, Predicting efficacy of anti infectives with pharmacodynamics and Monte Carlo simulation: CME REVIEW ARTICLE, *The Pediatric Infectious Disease Journal*, **22** (11), 982–992

Brenner, G.M. and Stevens, C.W., 2017, Quinolones, Antifolate Drugs, and Other Antimicrobial Agents, in: *Pharmacology*, 4th Ed., Elsevier Health Sciences, Chapter 40, pp. 417–423

Brogden, R.N. and Spencer, C.M., 1997, Cefotaxime: A Reappraisal of its Antibacterial Activity and Pharmacokinetic Properties, and a Review of its Therapeutic Efficacy When Administered Twice Daily for the Treatment of Mild to Moderate Infections, *Drugs*, **53**, 483–510

Carpenter, H.A., 1998. Bacterial and Parasitic Cholangitis. Mayo Clin. Proc. 73, 473–478. https://doi.org/10.1016/S0025-6196(11)63734-8

Chan, C.C., Lam, H., Lee, Y.C. and Zhang, X.M., 2004, Analytical Method Validation and Instrument Performance Verification, John Wiley & Sons, Inc., Hoboken, New Jersey

Czyrski, A. and Szałek, E., 2016, An HPLC method for levofloxacin determination and its application in biomedical analysis, *Journal of Analytical Chemistry*, **71**, 840–843

Dabhi, B., Parmar, B., Patel, N., Jadeja, Y., Patel, M., Jebaliya, H., et.al., 2013, A Stability Indicating UPLC Method for the Determination of Levofloxacin Hemihydrate in Pharmaceutical Dosage Form: Application to Pharmaceutical Analysis, *Chromatography Research International*, 1-5

Davin-Regli, A. and Pagès, J.-M., 2015, Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment, *Frontiers in Microbiology*, **6**, 392

Ekinci, B., Coban, A.Y., Birinci, A., Durupinar, B., Erturk, M., 2002, In vitro effects of cefotaxime and ceftriaxone on Salmonella typhi within human monocyte-derived macrophages, Clin. Microbiol. Infect., 8, 810–813. https://doi.org/10.1046/j.1469-0691.2002.00457.x

Eric-Jovanovic, S., Agbaba, D., Zivanov-Stakic, D. and Vladimirov, S., 1998, HPTLC determination of ceftriaxone, cefixime and cefotaxime in dosage forms, *Journal of Pharmaceutical and Biomedical Analysis*, **18**, 893–898

European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters, 2022, viewed 12 August 2023,

<https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf>

European Committee on Antimicrobial Susceptibility Testing. Ciprofloxacin: Rationale for EUCAST Clinical Breakpoints, 2021, viewed 20 September 2023, <https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Ciprofloxacin_Rationale_Document_2.0_20210101.pdf>

European Committee on Antimicrobial Susceptibility Testing. Enterobacterales Calibration of zone diameter breakpoints to MIC values, 2023, Version 11, viewed 20 September 2023, <https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_criteria/Validation_2023/Enterobacterales_v_11.0_February_2023.pdf>

European Medicines Agency, 2011, Guideline on Bioanalytical Method Validation, EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2** in *Committee for Medicinal Products for Human Use (CHMP)*, viewed 18 April 2023, < https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf>

Ferro, J.R., Lionel Lewis, Timothy Mant and Albert, 2008, Therapeutic drug monitoring, i*n: A Textbook of Clinical Pharmacology and Therapeutics*, 5th Ed., CRC Press

Fiore, E., Van Tyne, D. and Gilmore, M.S., 2019, Pathogenicity of Enterococci, *Microbiology Spectrum*, American Society for Microbiology, **7**

Fu, K.P., Aswapokee, P., Ho, I., Matthijssen, C. and Neu, H.C., 1979, Pharmacokinetics of cefotaxime, *Antimicrobial Agents and Chemotherapy*, **16**, 592–597

Gieling, E.M., Wallenburg, E., Frenzel, T., de Lange, D.W., Schouten, J.A., ten Oever, J., et.al., 2020, Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility, *Clinical Pharmacology and Therapeutics*, **108**, 770–774

Goudarzi, M., Goudarzi, H., Alebouyeh, M., Azimi Rad, M., Shayegan Mehr, F.S., Zali, M.R. and Aslani, M.M., 2013, Antimicrobial Susceptibility of Clostridium Difficile Clinical Isolates in Iran, *Iranian Red Crescent Medical Journal*, **15**, 704–711

Gross, A.S., 1998, Best practice in therapeutic drug monitoring, *British Journal of Clinical Pharmacology*, **46**, 95–99

Guerra Valero, Y.C., Dorofaeff, T., Roberts, J.A., Lipman, J., Coulthard, M.G., Sparkes, L., et. al., 2021, Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children, *Analytical and Bioanalytical Chemistry*, **413**, 4483–4491

Hajjar, R., Ambaraghassi, G., Sebajang, H., Schwenter, F. and Su, S.-H., 2020, Raoultella ornithinolytica: Emergence and Resistance, *Infection and Drug Resistance*, **13**, 1091–1104

Hakim, L., Bourne, D.W.A. and Triggs, E.J., 1988, High-performance liquid chromatographic assay of cefotaxime, desacetylcefotaxime and ceftriaxone in rat plasma, *Journal of Chromatography B: Biomedical Sciences and Applications*, **424**, 111–117

Höffken, G., Lode, H., Prinzing, C., Borner, K. and Koeppe, P., 1985, Pharmacokinetics of ciprofloxacin after oral and parenteral administration, *Antimicrobial Agents and Chemotherapy*, **27**, 375–379

Imre, S., Dogaru, M.T., Vari, C.E., Muntean, T. and Kelemen, L., 2003, Validation of an HPLC method for the determination of ciprofloxacin in human plasma, *Journal of Pharmaceutical and Biomedical Analysis*, **33**, 125–130

Jacobs, R.F., Kaplan, S.L., Schutze, G.E., Dajani, A.S., Leggiadro, R.J., Rim, C.S., et. al., 1996, Relationship of MICs to efficacy of cefotaxime in treatment of Streptococcus pneumoniae infections, *Antimicrobial Agents and Chemotherapy*, **40**, 895–898

Jeffres, M.N., Shuster, J.E. and Barclay, S.M., 2011, Treatment of ciprofloxacin nonsusceptible urinary tract infections with ciprofloxacin, *Annals of Pharmacotherapy*, **45** (6)

Jones, M.W., Lopez, R.A., Deppen, J.G., 2023. Appendicitis, in: StatPearls. StatPearls Publishing, Treasure Island (FL).

Kang, J.-S. and Lee,M.-H., 2009, Overview of Therapeutic Drug Monitoring, *The Korean journal of internal medicine*, **24**, 1–10

Kassim, A., Omuse, G., Premji, Z. and Revathi, G., 2016, Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at University teaching hospital in Nairobi, Kenya: a cross-sectional study, *Annals of Clinical Microbiology and Antimicrobials*, **15** (1), 21

Kaya, S., Bayramoğlu, G., Sönmez, M. and Köksal, İ., 2015, Raoultella ornithinolytica causing fatal sepsis, *The Brazilian Journal of Infectious Diseases*, **19**, 230–231

Kementrian Kesehatan, 2015, Mengenal Bakteri Listeria Monocytogenes, *Sehat Negeriku*, viewed 29 August 2023, <https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20150127/2711851/mengenal-bakteri-listeria-monocytogenes/

Kocsis, B., Domokos, J., Szabo, D., 2016, Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann. Clin. Microbiol. Antimicrob. 15, 34. https://doi.org/10.1186/s12941-016-0150-4

Lameirão Gomes, C., Violante Silva, R., Carrola, P., Presa, J., 2019, Bacterial Infections in Patients with Liver Cirrhosis in an Internal Medicine Department. GE Port. J. Gastroenterol, 26, 324–332, https://doi.org/10.1159/000494568

Leekha, S., Terrell, C.L. and Edson, R.S., 2011, General Principles of Antimicrobial Therapy, *Mayo Clinic Proceedings*, **86**, 156–167

Lefeuvre, S., Bois-Maublanc, J., Hocqueloux, L., Bret, L., Francia, T., Eleout-Da violante, C., et. al., 2017, A simple ultra-high-performance liquid chromatography-high resolution mass spectrometry assay for the simultaneous quantification of 15 antibiotics in plasma, *Journal of Chromatography B*, **1065–1066**, 50–58

Lemmen, S., Kropec, A., Engels, I., Busse, A. and Daschner, F.D., 1993, Serum bactericidal activity after administration of four cephalosporins in healthy volunteers, *Eur J Clin Microbiol Infect Dis*, **12**, 856–860

Ling, S.S.N., Yuen, K.H. and Barker, S.A., 2003, Simple liquid chromatographic method for the determination of cefotaxime in human and rat plasma, *Journal of Chromatography B*, **783**, 297–301

Marchese, A., Esposito, S., Barbieri, R., Bassetti, M. and Debbia, E., 2012, Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?, *BMC Infectious Diseases*, **12**, 181

Markowitz, J.S., Gill, H.S., Devane, C.L., Mintzer, J.E., 1997, Fluoroquinolone inhibition of clozapine metabolism, *American Journal of Psychiatry*, **154** (6), 881a–8881

McKinnon, P.S., Paladino, J.A. and Schentag, J.J., 2008, Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T> MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections, *International journal of antimicrobial agents*, **31**, 345–351

Meyer, J.M., Proctor, G., Cummings, M.A., Dardashti, L.J. and Stahl, S.M., 2016, Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction, *Case Reports in Psychiatry*, 1–7.

Moradali, M.F., Ghods, S. and Rehm, B.H.A., 2017, Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence, *Frontiers in Cellular and Infection Microbiology*, 7.

Mouton, J.W., Vinks, A.A. and Punt, N.C., 1997, Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion, *Antimicrobial agents and chemotherapy*, **41**, 733–738.

Mukti, A.A., Jannah, F., Nurrochmad, A. and Lukitaningsih, E., 2016, Development and validation method for quantitative determination of ciprofloxacin in human plasma and its application in bioequivalence test, *Asian Journal of Pharmaceutical and Clinical Research*, **9,** 3

N, L. and Pn, S.P., 2010. Development and validation of RP-HPLC method for estimation of Cefotaxime sodium in marketed formulations, *Journal of Basic and Clinical Pharmacy*, **1**

National Center for Biotechnology Information, 2023, PubChem Compound Summary for CID 2764, Ciprofloxacin, Retrieved September 3, 2023 from https://pubchem.ncbi.nlm.nih.gov/compound/Ciprofloxacin

Novakovic, J., Nesmerak, K., Nova, H. and Filka, K., 2001, An HPTLC method for the determination and the purity control of ciprofloxacin HCl in coated tablets, *Journal of Pharmaceutical and Biomedical Analysis*, **25**, 957–964

Payne, O.B. and Ericson, J.E., 2019, Chapter 2 - Empiric Antimicrobials for Neonatal Sepsis, in: Benitz, W.E., Smith, P.B. (Eds.), *Infectious Disease and Pharmacology*, Elsevier, Philadelphia, pp. 15–25

Pea, F., 2006, Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective, *The Journal of antimicrobial chemotherapy*, **58**, 380–386

Peikova, L., Tzankova, D., Smerikarova, M., Balkanski, S. and Zlatkov, A., 2022, Development of RP-HPLC methods for the analysis of Dexamethasone and Levofloxacin alone and in combinations used in the therapy of Covid-19. *Pharmacia*, **69**, 1075–1080.

Prahesti, K.I., Mayasari, N.L.P.I., Malaka, R., Yuliati, F.N. and Pasaribu, F.H., 2018, Isolasi dan Identifikasi Bakteri Listeria monocytogenes dari Susu Sapi Segar di Kabupaten Enrekang Sulawesi Selatan, Acta VETERINARIA Indonesiana, **5**, 57–65

Pulian Morais, V., Daporta, M.T., Bao, A.F., Campello, M.G., Quindós Andrés, G., 2009, Enteric Fever-Like Syndrome Caused by Raoultella ornithinolytica (Klebsiella ornithinolytica), *Journal of Clinical Microbiology*, **47**, 868–869.

Raaska, K. and Neuvonen, P.J., 2000, Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia, *European Journal of Clinical Pharmacology*, **56**, 585–589, https://doi.org/10.1007/s002280000192

Rahman, A.O., 2017, Uji Kepekaan Bakteri yang Diisolasi dari Pasien dengan Bakteriuria terhadap Antibiotik Amoksisilin, Levofloksasin dan Ciprofloksasin di Laboratorium Mikrobiologi RSUD Raden Mattaher Jambi Periode Oktober - November 2016, *Jurnal Online Jambi*, **5**, 87–94

Rawla, P., Bandaru, S.S., Vellipuram, A.R., 2017, Review of Infectious Etiology of Acute Pancreatitis. Gastroenterol. Res, 10, 153–158, https://doi.org/10.14740/gr858w

Reis, A.C.C., Santos, S.R. da S., de Souza, S.C., Saldanha, M.G., Pitanga, T.N. and Oliveira, R.R., 2016, Ciprofloxacin Resistance Pattern Among Bacteria Isolated from Patients with Community-acquired Urinary Tract Infection, *Revista do Instituto de Medicina Tropical de São Paulo*, **58**, 53

Roberts, J.A., Norris, R., Paterson, D.L. and Martin, J.H., 2012, Therapeutic drug monitoring of antimicrobials: Therapeutic drug monitoring of antimicrobials, *British Journal of Clinical Pharmacology*, **73**, 27–36, https://doi.org/10.1111/j.1365-2125.2011.04080.x

Rodloff, A., Bauer, T., Ewig, S., Kujath, P. and Müller, E., 2008, Susceptible, Intermediate, and Resistant – The Intensity of Antibiotic Action, *Deutsches Ärzteblatt International*, **105**, 657–662

Roosendaal, R., Bakker-Woudenberg, I.A.J., Van den Berghe-Van Raffe, M., Vink-Van den Berg, J.C. and Michel, M.F., 1989, Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats, *Eur. J. Clin. Microbiol. Infect. Dis.*, **8**, 878–887

RSUP Dr. Sardjito, 2023, Peradangan Hidung dan Sinus (Rhinosinusitis), https://sardjito.co.id/2019/10/30/peradangan-hidung-dan-sinus-rhinosinusitis/ (accessed 7.28.23).

Ryan, D.M., 1993, Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans, *J. Antimicrob. Chemother.*, **31**, 1–16.

Scheer, F., 2014, Pharmacokinetics of Piperacillin and Ciprofloxacin in Critically Ill Patients Undergoing Continuous Venovenous Haemodialysis or Haemodiafiltration, *J. Pharm. Care Health Syst*, **01**

Selleck, E.M., Van Tyne, D. and Gilmore, M.S., 2019, Pathogenicity of Enterococci, *Microbiology spectrum*, **7** (4)

Shearer, M.J., Bechtold, H., Andrassy, K., Koderisch, J., McCarthy, P.T., Trenk, D., Jähnchen, E. and Ritz, E., 1988, Mechanism of Cephalosporin-induced Hypoprothrombinemia: Relation to Cephalosporin Side Chain, Vitamin K Metabolism, and Vitamin K Status, *J. Clin. Pharmacol*, **28**, 88–95

Sinha, S., Bhavsar, S.K. and Thaker, A.M., 2015, Development and validation of HPLC method for quantification of Cefotaxime in plasma of Patanwadi sheep, *Exploratory Animal and Medical Research*, **5,** 190–195.

Sza, E., Kami, A., GOèDZIK-SPYCHALSKA, J., GRZEåKOWIAK, E. and Batura-Gabryel, H., 2011, The PK/PD Index (Cmax/MIC) for Ciprofloxacin in Patients with Cystic Fibrosis, *Acta Pol. Pharm*, **68**, 777–783

Talib Humeidy, I., 2021, Spectrophotometric determination of cefotaxime sodium in pharmaceutical formulations, *Materials Today: Proceedings*, **47**, 6043–6049

Tam, V.H., Schilling, A.N., Neshat, S., Poole, K., Melnick, D.A. and Coyle, E.A., 2005, Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa, Antimicrobial agents and chemotherapy, **49**, 4920–4927

Todd, P.A. and Brogden, R.N., 1990. Cefotaxime: An Update of its Pharmacology and Therapeutic Use. *Drugs*, **40**, 608–651

Van Der Linden, P.D., Sturkenboom, M.C.J.M., Herings, R.M.C., Leufkens, H.M.G., Rowlands, S. and Stricker, B.H.Ch., 2003, Increased Risk of Achilles Tendon Rupture With Quinolone Antibacterial Use, Especially in Elderly Patients Taking Oral Corticosteroids, *Archives of Internal Medicine*, **163**, 1801

Van Tyne, D., Martin, M.J. and Gilmore, M.S., 2013, Structure, Function, and Biology of the Enterococcus faecalis Cytolysin, *Toxins*, 5, 895–911

Vance-Bryan, K., Guay, D.R.P. and Rotschafer, J.C., 1990, Clinical Pharmacokinetics of Ciprofloxacin, *Clinical Pharmacokinetics*, **19**, 434–461

Verghese, V.P., Veeraraghavan, B., Jayaraman, R., Varghese, R., Neeravi, A., Jayaraman, Y., et.al., 2017, Increasing incidence of penicillin- and cefotaxime-resistant Streptococcus pneumoniae causing meningitis in India: Time for revision of treatment guidelines?, I*ndian Journal of Medical Microbiology*, **35**, 228–236.

Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S. and Craig, W.A., 1988a. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model, *J. Infect. Dis*, **158**, 831–847.

Vogelman, B., Gudmundsson, S., Turnidge, J., Leggett, J. and Craig, W.A., 1988b. In vivo postantibiotic effect in a thigh infection in neutropenic mice, *J. Infect. Dis*, **157**, 287–298.

Wade, K.C. and Benjamin, D.K., 2011, Clinical Pharmacology of Anti-Infective Drugs, in: *Infectious Diseases of the Fetus and Newborn*, Elsevier, pp. 1160–1211

Wang, J.-T., Chen, P.-C., Chang, S.-C., Shiau, Y.-R., Wang, H.-Y., Lai, J.-F., et.al., 2014, Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program, *BMC Infect. Dis*, **14**, 486.

Watabe, S., Yokoyama, Y., Nakazawa, K., Shinozaki, K., Hiraoka, R., Takeshita, K. and Suzuki, Y., 2010, Simultaneous measurement of pazufloxacin, ciprofloxacin, and levofloxacin in human serum by high-performance liquid chromatography with fluorescence detection, *J. Chromatogr. B*, **878**, 1555–1561

Wiffen, P. (Ed.), 2012, Oxford handbook of clinical pharmacy, 2nd Ed., *Oxford medical publications*, Oxford University Press, New York.

Wishart, D., Feunang, Y., Guo, A., Lo, E., Marcu, A., Grant, J., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., Wilson, M., 2017, Ciprofloxacin - DrugBank [WWW Document]. *DrugBank* 50 Major Update DrugBank Database 2018Nucleic Acids Res 2017 Nov 8 Doi 101093nargkx1037. <https://www.drugbank.ca/drugs/DB00537> (accessed 1.17.18)